U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. PerkinElmer Health Sciences, Inc. - 01/13/2017
  1. Warning Letters

CLOSEOUT LETTER

PerkinElmer Health Sciences, Inc.


Recipient:
PerkinElmer Health Sciences, Inc.

United States

Issuing Office:

United States


 

  

Black HHS-Blue FDA Logo

 

 

 
10903 New Hampshire Avenue
Silver Spring, MD 20993 

JAN 13, 2017

Kay A. Taylor
VP of Global Regulatory, Quality and Clinical Affairs
PerkinElmer Inc.
940 Winter Street
Waltham, MA 02451

Dear Ms. Taylor:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 407102 dated October 23, 2014. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these conections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Donald J. St. Pierre
Acting Deputy Director for
Patient Safety and Product Quality
Office of InVitro Diagnotics and
Radiological Health
Center tor Devices and Radiological Health

Back to Top